Leveraging Real-World Evidence for drug approval

The FDA approved it in 2016, but the question remains: Is real-world evidence a suitable substitute for randomized clinical trials? Knect365 interviews Dan Danielson, Senior Director of the Access Experience Team at Precision for Value, on the opportunities and challenges of real-world evidence.

Read the article

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.